---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-007217"
form_type: "8-K"
ticker: "ZLAB"
cik: "0001704292"
company_name: "Zai Lab Ltd"
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T12:12:04.685608+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zai Lab FY2023 product revenue $266.7M (+25% YoY); VYVGART launch drives 2024 outlook >$70M

## Summary
- Product revenue $266.7M (+25% YoY; +31% CER); net loss narrowed to $334.6M from $443.3M.
- VYVGART launched Sept 2023; 2023 revenue $10M; ~1,000 patients treated in Jan 2024; 2024 guidance >$70M.
- ZEJULA $168.8M (+16% YoY); OPTUNE $47.0M (flat); QINLOCK $19.2M (+29%); NUZYRA $21.7M (+316%).
- Cash $807.6M (Dec 31, 2023) vs $1.0B year prior; R&D down, SG&A up on VYVGART launch.
- Targeting profitability by end of 2025; regulatory submissions expected for 4 new products in 2024.

## SEC filing metadata
- accession: 0001628280-24-007217
- form_type: 8-K
- ticker: ZLAB
- cik: 0001704292
- company_name: Zai Lab Ltd
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704292/000162828024007217/0001628280-24-007217-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704292/000162828024007217/zlab-20240227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-007217
- JSON: https://secwatch.observer/filing/0001628280-24-007217.json
- Plain text: https://secwatch.observer/filing/0001628280-24-007217.txt

## Key facts
- Earnings Releases
  Zai Lab Ltd reported the year ended December 31, 2023 results: revenue $266.7 million, net income $334.6 million, EPS loss per ordinary share attributable to common stockholders of $0.35 (or loss per American Deposit Share ("ADS") of $3.4.
  - Period: the year ended December 31, 2023
  - Revenue: $266.7 million
  - Net income: $334.6 million
  - EPS: loss per ordinary share attributable to common stockholders of $0.35 (or loss per American Deposit Share ("ADS") of $3.4
  - Result: reported results
  source text: by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates – Total product revenue of $266.7 million for Full-Year 2023, representing 25% y-o-y growth; 31% y-o-y growth at constant exchange rate (CER) – VYVGART ® (efgartigimod alfa injection) was launched in September 2023 in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1704292/000162828024007217/0001628280-24-007217-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.